Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Cytek Biosciences (CTKB) Shares Repurchased (2023 - 2025)

Cytek Biosciences filings provide 3 years of Shares Repurchased readings, the most recent being -$34000.0 for Q4 2025.

On a quarterly basis, Shares Repurchased fell 100.49% to -$34000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $15.1 million, a 30.28% decrease, with the full-year FY2025 number at $15.1 million, down 30.25% from a year prior.
Shares Repurchased hit -$34000.0 in Q4 2025 for Cytek Biosciences, down from -$29000.0 in the prior quarter.
In the past five years, Shares Repurchased ranged from a high of $34.6 million in Q4 2023 to a low of -$34000.0 in Q4 2025.
Median Shares Repurchased over the past 3 years was $7.0 million (2024), compared with a mean of $8.9 million.
The widest YoY moves for Shares Repurchased: up 68.91% in 2025, down 100.49% in 2025.
Cytek Biosciences' Shares Repurchased stood at $34.6 million in 2023, then crashed by 79.77% to $7.0 million in 2024, then crashed by 100.49% to -$34000.0 in 2025.
The last three reported values for Shares Repurchased were -$34000.0 (Q4 2025), -$29000.0 (Q3 2025), and $4.5 million (Q2 2025) per Business Quant data.